Untreated hepatitis C virus genotype 1-infected patients achieved a sustained virologic response 12 weeks after treatment with ombitasvir and dasabuvir, with ribavirin, according to data from a recent study.
Researchers randomized and divided 631 patients into two groups (A, B) in a double-blind, placebo-controlled trial. Group A patients (431) received an oral regimen of ABT-450/r-ombitasvir (a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir and 25 mg of ombitasvir) and 250 mg of dasabuvir (twice daily) with ribavirin. Group B (158) received matching placebos. After the double-blind period, Group B received the active regimen as open-label therapy for 12 weeks. The mean age of group A was 49.4 years and group B was 521.2 years. The primary endpoint was sustained virologic response (SVR) at 12 weeks after treatment.Full Story »